Stocks News

LAST PRICE
478.0900
TODAY'S CHANGE (%)
Trending Up5.2900 (1.1189%)

Bid / Lots
477.0200/ 2
Ask / Lots
480.2400/ 2
Open / Previous Close
483.0000 / 472.8000
Day Range
Low 474.0001
High 486.2300
52 Week Range
Low 341.9000
High 510.6350
Volume
45,874
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $451 From $437, Maintains Sector Perform Rating, from 10 minutes ago by MT Newswires
  10 minutes ago by MT Newswires
  Companies Mentioned: VRTX
  09:39 AM EST, 11/05/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $602, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic...
- DJ Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley, from 1 hour ago by Dow Jones
  1 hour ago by Dow Jones
  Companies Mentioned: VRTX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/VRTX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 05, 2024 08:34 ET (13:34 GMT)
- Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $476 From $473, Maintains Equalweight Rating, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: VRTX
  06:42 AM EST, 11/05/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $602, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic...
- Scotiabank Adjusts Price Target on Vertex Pharmaceuticals to $486 From $480, Maintains Sector Perform Rating, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: VRTX
  06:42 AM EST, 11/05/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $602, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic...
- Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $506 From $502, Maintains Market Perform Rating, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: VRTX
  06:42 AM EST, 11/05/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $602, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic...

Today
- JPMorgan Cuts Price Target on IQVIA to $240 From $279, Maintains Overweight Rating, from 2 hours ago by MT Newswires
  2 hours ago by MT Newswires
  Companies Mentioned: IQV
Yesterday
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 18 hours ago by Dow Jones
  18 hours ago by Dow Jones
  Companies Mentioned: REGN
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 20 hours ago by Dow Jones
  20 hours ago by Dow Jones
  Companies Mentioned: REGN
- DJ IQVIA Holdings Is Maintained at Buy by Truist Securities, from 23 hours ago by Dow Jones
  23 hours ago by Dow Jones
  Companies Mentioned: IQV
- DJ Biogen Is Maintained at Neutral by JP Morgan, from 9:47AM ET on Monday Nov 04, 2024 by Dow Jones
  9:47AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: BIIB
- DJ IQVIA Holdings Is Maintained at Overweight by Morgan Stanley, from 8:23AM ET on Monday Nov 04, 2024 by Dow Jones
  8:23AM ET on Monday Nov 04, 2024 by Dow Jones
  Companies Mentioned: IQV
Nov 1, 2024
- The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 3:44PM ET on Friday Nov 01, 2024 by Dow Jones
  3:44PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: REGN
- DJ IQVIA Holdings Is Maintained at Buy by BTIG, from 3:14PM ET on Friday Nov 01, 2024 by Dow Jones
  3:14PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: IQV
- DJ IQVIA Holdings Is Maintained at Buy by TD Cowen, from 2:52PM ET on Friday Nov 01, 2024 by Dow Jones
  2:52PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: IQV
- DJ Regeneron Pharma Is Maintained at Overweight by Morgan Stanley, from 2:07PM ET on Friday Nov 01, 2024 by Dow Jones
  2:07PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: REGN

Vertex Pharmaceuticals Inc
NASDAQ:VRTXUnited States

Search Criteria

Today

RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $451 From $437, Maintains Sector Perform Rating, from 10 minutes ago by MT Newswires

DJ Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley, from 1 hour ago by Dow Jones

Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $476 From $473, Maintains Equalweight Rating, from 3 hours ago by MT Newswires

Scotiabank Adjusts Price Target on Vertex Pharmaceuticals to $486 From $480, Maintains Sector Perform Rating, from 3 hours ago by MT Newswires

Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $506 From $502, Maintains Market Perform Rating, from 3 hours ago by MT Newswires

Peers Headlines

Today

JPMorgan Cuts Price Target on IQVIA to $240 From $279, Maintains Overweight Rating, from 2 hours ago by MT Newswires

Yesterday

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 18 hours ago by Dow Jones

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 20 hours ago by Dow Jones

DJ IQVIA Holdings Is Maintained at Buy by Truist Securities, from 23 hours ago by Dow Jones

DJ Biogen Is Maintained at Neutral by JP Morgan, from 9:47AM ET on Monday Nov 04, 2024 by Dow Jones

DJ IQVIA Holdings Is Maintained at Overweight by Morgan Stanley, from 8:23AM ET on Monday Nov 04, 2024 by Dow Jones

Nov 1, 2024

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 3:44PM ET on Friday Nov 01, 2024 by Dow Jones

DJ IQVIA Holdings Is Maintained at Buy by BTIG, from 3:14PM ET on Friday Nov 01, 2024 by Dow Jones

DJ IQVIA Holdings Is Maintained at Buy by TD Cowen, from 2:52PM ET on Friday Nov 01, 2024 by Dow Jones

DJ Regeneron Pharma Is Maintained at Overweight by Morgan Stanley, from 2:07PM ET on Friday Nov 01, 2024 by Dow Jones